Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Non-Current Debt: 2017

Historic Non-Current Debt for Cidara Therapeutics (CDTX) over the last 1 years, with Dec 2017 value amounting to $7.2 million.

  • Cidara Therapeutics' Non-Current Debt rose 13.05% to $9.3 million in Q3 2018 from the same period last year, while for Sep 2018 it was $9.3 million, marking a year-over-year increase of 13.05%. This contributed to the annual value of $7.2 million for FY2017, which is N/A change from last year.
  • Latest data reveals that Cidara Therapeutics reported Non-Current Debt of $7.2 million as of FY2017.
  • Over the past 5 years, Cidara Therapeutics' Non-Current Debt peaked at $7.2 million during FY2017, and registered a low of $7.2 million during FY2017.
  • For the 1-year period, Cidara Therapeutics' Non-Current Debt averaged around $7.2 million, with its median value being $7.2 million (2017).